will pp405 be able to bring my lost temple area back to the game? 3/29/2026
A user is concerned about hair loss in the temple area despite using Minoxidil and finasteride for 10 months and is curious if PP405 can help. Responses indicate uncertainty about PP405's effectiveness, with some optimism about future treatments and AI speeding up drug discovery, but emphasize waiting for clinical trial results.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Solving Hair Loss with Research at MIT
Hair loss treatments like minoxidil, finasteride, TDM-105795, and PP405. MIT is hosting a hackathon to find innovative hair loss solutions.
community I hope ET-02 or PP405 will be released in the next 4-5 years
PP405 is a potential hair loss treatment that may work by blocking signals that cause hair cells to stop growing, requiring daily application for effectiveness. It could serve as an alternative to minoxidil and finasteride, but it is not yet available on the market and may take several years to be released.
community Latest news about pp405 (source: Christina Weng's Instagram channel)
A new hair loss treatment, pp405, may regrow hair better than finasteride and minoxidil, with potential availability by 2028. However, there is skepticism about its effectiveness and commercialization timeline.
community Why Fin/Dut Isn't Working for You GPR133: a new hairloss mechanism + Steroid Hair Loss Deep Dive
Hair loss may be linked to the GPR133 receptor, independent of the androgen receptor pathway. Treatments like finasteride, dutasteride, minoxidil, RU58841, and KX-826 show varying results, with hair loss persisting due to high testosterone and GPR133's role.
community Anybody else obsessively searching for pp405 and counting the days?
People are eagerly awaiting the release of PP405, a new hair loss treatment. Some are using minoxidil and finasteride in the meantime, but there are concerns about scams and unverified products.
Related Research
6 / 6 results
research PP405 in Alopecia: An Emerging Molecule worth Investigating
In this study, the novel topical agent PP405 showed favorable tolerability and increased hair density by over 20% in men with advanced androgenetic alopecia after eight weeks, suggesting a promising potential treatment pending further trials.
research Beyond Minoxidil: Off-Label Therapies for Male Androgenetic Alopecia—A Systematic Review with Network Meta-Analyses
In this network meta-analysis, the researchers reported that topical minoxidil 5% was the most effective off-label therapy for increasing hair density in men with androgenetic alopecia, while other treatments like melatonin and cetirizine showed potential benefits, highlighting a need for further comparative trials.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.
research Recent Advances in Drug Development for Hair Loss
This review highlights the limitations of existing hair loss treatments like minoxidil and finasteride and suggests that future therapies may benefit from focusing on antibody and cell-based treatments, which offer targeted and potentially transformative options for managing hair loss disorders.
research Emerging pharmacotherapies for Androgenetic Alopecia
This article reviews emerging therapies for androgenetic alopecia, highlighting advances like androgen-receptor antagonists and improved minoxidil delivery that aim to enhance treatment efficacy and safety.
research ПОРІВНЯЛЬНИЙ АНАЛІЗ МЕТОДІВ ВІДНОВЛЕННЯ ВОЛОССЯ В УКРАЇНІ ТА США
This research provides a comprehensive comparison of hair restoration methods used in Ukraine and the USA, examining the effectiveness of surgical and non-surgical treatments for alopecia, including FUE and FUT hair transplantation, PRP therapy, and low-level laser therapy.